Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  Indivior    INDV   GB00BRS65X63

INDIVIOR

(INDV)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Indivior : to 'vigorously defend' Reckitt Benckiser's $1.4 billion claim

11/30/2020 | 03:06am EST
Products produced by Reckitt Benckiser; Vanish, Finish, Dettol and Harpic are seen in London

(Reuters) - British drugmaker Indivior Plc said on Monday it would "vigorously defend" against a 1.07 billion pound ($1.43 billion) legal claim from consumer good maker Reckitt Benckiser Group relating to their demerger agreement.

The company "Strongly believes that the claim is without merit and that it has strong grounds for defending against the claim should it be served," said Indivior, which was spun off from Reckitt in 2014.

Indivior said that the claim has not been served yet.

Last week, the British drugmaker disclosed that Reckitt had submitted a 1.07 billion pound claim earlier this month to the Commercial Court in London against Indivior relating to their demerger agreement.

(Reporting by Aakash Jagadeesh Babu in Bengaluru, Editing by Sherry Jacob-Phillips)


© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
INDIVIOR 9.81% 115.3 Delayed Quote.5.97%
RECKITT BENCKISER GROUP PLC -0.82% 6274 Delayed Quote.-4.10%
All news about INDIVIOR
01/15INDIVIOR : The Department of Health and Human Services Announces New Guidance In..
PU
01/15LONDON STOCK EXCHANGE : FTSE 100 logs worst week since October-end on lockdown w..
RE
01/15INDIVIOR : Provides Preliminary FY 2020 Financial Results Ahead of Guidance
PU
01/15INDIVIOR : raises revenue forecast as U.S. opioid treatment sales recover
RE
01/15INDIVIOR : Lifts Net Revenue Guidance for 2020, Flags Higher-than-Expected Adjus..
MT
01/12INDIVIOR : Directorate Change
PU
01/12PRESS RELEASE : Addex to Present at the Baader Helvea Swiss Equities Conference
DJ
01/11PRESS RELEASE : Addex Successfully Completes $11.5 Million Capital Increase Incl..
DJ
2020INDIVIOR : Claim filed by Reckitt Benckiser Group
PU
2020PRESS RELEASE : Addex Announces Filing of Registration Statement for Proposed Pu..
DJ
More news
Financials (USD)
Sales 2020 633 M - -
Net income 2020 -118 M - -
Net cash 2020 603 M - -
P/E ratio 2020 -9,33x
Yield 2020 -
Capitalization 1 149 M 1 150 M -
EV / Sales 2020 0,86x
EV / Sales 2021 0,90x
Nbr of Employees 796
Free-Float 98,3%
Chart INDIVIOR
Duration : Period :
Indivior Technical Analysis Chart | INDV | GB00BRS65X63 | MarketScreener
Technical analysis trends INDIVIOR
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Average target price 2,86 $
Last Close Price 1,57 $
Spread / Highest target 180%
Spread / Average Target 82,5%
Spread / Lowest Target 35,9%
EPS Revisions
Managers and Directors
NameTitle
Mark Crossley Executive Director, CEO & COO
Graham C. Hetherington Chairman
Ryan Preblick Chief Financial Officer & Executive Director
Christian Heidbreder Chief Scientific Officer
A. Thomas McLellan Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
INDIVIOR5.97%1 150
MERCK KGAA6.09%79 055
ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL., LTD6.24%27 322
KYOWA KIRIN CO., LTD.0.14%14 451
BETTA PHARMACEUTICALS CO., LTD.12.74%7 513
YUHAN CORPORATION1.60%4 412